title: TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.
abstract: BACKGROUND
  We have previously shown that transducin-like enhancer of split 3 (TLE3) is associated with outcome specifically in patients with taxane-treated breast cancer and not in patients treated with anthracycline-based regimens without a taxane. The purpose of this study was to assess the association between TLE3 expression and recurrence in patients with ovarian carcinoma treated with a taxane containing regimen as opposed to those treated with a platinum-based agent alone.
  
  
  METHODS
  We carried out immunohistochemical staining of TLE3 in two series of ovarian cancer specimens from the University of Alabama at Birmingham, Birmingham, AL and the Royal Hospital for Women, Sydney, Australia. Local and distant recurrences within the first five years of follow-up were analyzed using Kaplan-Meier, Cox proportional hazard, and multivariate analysis to assess an association between TLE3 expression and response to therapy.
  
  
  RESULTS
  TLE3 was expressed in approximately 30% of tumors and expression was associated with a favorable outcome only in patients who had received taxane as part of their treatment regimen (n = 173, HR = 0.62, P = 0.012; P(interaction) = 0.024). Further analysis revealed that the predictive association between TLE3 expression and outcome was strongest in patients with nonserous histology.
  
  
  CONCLUSIONS
  High TLE3 expression predicts a favorable response to taxane containing chemotherapy regimens in ovarian carcinoma.
  
  
  CONCLUSIONS
  Our findings warrant an independent evaluation of TLE3 as a potential therapeutic response marker for taxane-based chemotherapy in ovarian cancer.
authors.affiliation: Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia. g.samimi@garvan.org.au
authors.forename: Goli
authors.initials: G
authors.lastname: Samimi
authors.forename: Brian Z
authors.initials: BZ
authors.lastname: Ring
authors.forename: Doug T
authors.initials: DT
authors.lastname: Ross
authors.forename: Robert S
authors.initials: RS
authors.lastname: Seitz
authors.forename: Robert L
authors.initials: RL
authors.lastname: Sutherland
authors.forename: Philippa M
authors.initials: PM
authors.lastname: O'Brien
authors.forename: Neville F
authors.initials: NF
authors.lastname: Hacker
authors.forename: Warner K
authors.initials: WK
authors.lastname: Huh
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000096:biosynthesis; D001952:Bridged-Ring Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D000077216:Carcinoma, Ovarian Epithelial; D056970:Co-Repressor Proteins / Q000096:biosynthesis*; D015331:Cohort Studies; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D015999:Multivariate Analysis; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D016016:Proportional Hazards Models; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D001952:Bridged-Ring Compounds; D056970:Co-Repressor Proteins; C570667:TLE3 protein, human; D043823:Taxoids; C080625:taxane